title: Venous thrombembolism, thrombophilic defects, combined oral contraception and anticoagulation.
abstract: BACKGROUND
  Several genetic polymorphisms increase the risk for venous thrombembolism (VTE). In particular, combined oral contraceptives (COCs) are known to enhance the risk for VTE and are therefore contraindicated.
  
  
  METHODS
  We present here the case of a patient with protein S deficiency, who has used COCs together with anticoagulatory therapy (Phenprocoumon) after suffering from deep venous thromboses for 4 years. At the time of her first consultation at our clinic, the ultrasound examination showed a complete involution of her venous thrombosis.
  
  
  CONCLUSIONS
  COCs can be used in patients with thrombogenic mutations and anticoagulatory therapy in individual cases.
authors.affiliation: Department of Gynaecologic Endocrinology and Reproductive Medicine, Medical University Vienna, Vienna, Austria. johannes.ott@meduniwien.ac.at
authors.forename: Johannes
authors.initials: J
authors.lastname: Ott
authors.forename: Regina
authors.initials: R
authors.lastname: Promberger
authors.forename: Ulrike
authors.initials: U
authors.lastname: Kaufmann
authors.forename: Johannes C
authors.initials: JC
authors.lastname: Huber
authors.forename: Peter
authors.initials: P
authors.lastname: Frigo
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D005260:Female; D006801:Humans; D010644:Phenprocoumon / Q000627:therapeutic use; D018455:Protein S Deficiency / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D020246:Venous Thrombosis / Q000139:chemically induced / Q000209:etiology* / Q000235:genetics / Q000473:pathology
chemical_list: D000925:Anticoagulants; D003277:Contraceptives, Oral, Combined; D010644:Phenprocoumon